Trials / Terminated
TerminatedNCT00189579
Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer
A Phase II Study Designed to Evaluate the Safety and Efficacy of the Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Early Relapse Patients (< 6 Months) With Ovarian Cancer, Overexpressing HER2, Previously Treated With Carboplatin-Paclitaxel
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- ARCAGY/ GINECO GROUP · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether or not the addition of Herceptin may be of benefit to a standard regimen of carboplatin-paclitaxel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Herceptin |
Timeline
- Completion
- 2007-01-01
- First posted
- 2005-09-19
- Last updated
- 2007-08-17
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00189579. Inclusion in this directory is not an endorsement.